| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000012275 |
| Receipt No. | R000014357 |
| Official scientific title of the study | Hangeshashinto for the prevention of oral mucositis in patients receiving with allogeneic hematopoietic stem cell transplantation |
| Date of disclosure of the study information | 2013/11/15 |
| Last modified on | 2016/11/22 (Ver. 4) |
| Basic information | ||
| Official scientific title of the study | Hangeshashinto for the prevention of oral mucositis in patients receiving with allogeneic hematopoietic stem cell transplantation | |
| Title of the study (Brief title) | Hangeshashinto for the prevention of oral mucositis in patients receiving with allogeneic hematopoietic stem cell transplantation | |
| Region |
|
|
| Condition | ||
| Condition | Hematological malignancy | |
| Classification by specialty |
|
|
| Classification by malignancy | Malignancy | |
| Genomic information | NO | |
| Objectives | |
| Narrative objectives1 | To investigate efficacy of Hangeshashinto for prevention of oral mucositis associated with hematopoietic stem cell transplantation |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | Incidence of CTCAE Grade3<=oral mucositis |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Single arm |
| Randomization | Non-randomized |
| Randomization unit | |
| Blinding | Open -no one is blinded |
| Control | Uncontrolled |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 1 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral administration of Hangeshashinto 7.5g/day t.i.d. after meals. | |
| Interventions/Control_2 | ||
| Interventions/Control_3 | ||
| Interventions/Control_4 | ||
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) acute leukemia, adult T cell leukemia/lymphoma, myelodysplastic syndrome, multiple myeloma, non-Hodgkin's lymphoma, Hodgkin's lymphoma.
2) Performance status : Eastern Cooperative Oncology Group (ECOG)<3 3) Patients must have adequate cardiac, hepatic, renal, and pulmonary functions. |
|||
| Key exclusion criteria | 1) Patients seropositive for HIV or HBs.
2) Severe psychiatric illness or any disorder that compromises ability to give truly informed consent for participation in this study. 3) Pregnant or breastfeeding women. 4) Patient has another progressive malignant disease. 5) Uncontrolled infections. 6) Acute Myocardial Infarction and heart failure within the last 12 months. 7) Liver cirrhosis. 8) BMI>=35. 9) Arrhythmias: CTCAE v4.0 Grade>=3. 10) Contraindication of Hangeshashinto. 11) Oral mucositis: CTCAE v3.0 Grade>=3. 12) Patients who, in the judgment of the investigator, would be inappropriate for entry into this study. |
|||
| Target sample size | 72 | |||
| Research contact person | |
| Name of lead principal investigator | Kohei Okada |
| Organization | Hokkaido University Hospital |
| Division name | Department of Hematology |
| Address | Nishi-5, Kita-14, Kita-ku, Sapporo, Hokkaido, Japan |
| TEL | 011-706-7214 |
| okada@med.hokudai.ac.jp | |
| Public contact | |
| Name of contact person | Kohei Okada |
| Organization | Hokkaido University Hospital |
| Division name | Department of Hematology |
| Address | Nishi-5, Kita-14, Kita-ku, Sapporo, Hokkaido, Japan |
| TEL | 011-706-7214 |
| Homepage URL | |
| okada@med.hokudai.ac.jp | |
| Sponsor | |
| Institute | North Japan Hematology Study Group |
| Institute | |
| Department | |
| Funding Source | |
| Organization | North Japan Hematology Study Group |
| Organization | |
| Division | |
| Category of Funding Organization | Other |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date | |||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| URL releasing results | |
| Results | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000014357 |